keynote - how do investigations in psycho-oncology inform clinical practice? (oct01
Post on 13-Sep-2014
849 views
DESCRIPTION
This is the opening keynote lecture from the IX Congresso Portugues de Psico-Oncologia in Porto (Oporto) Portugal 22-oct-2010.TRANSCRIPT
![Page 1: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/1.jpg)
Alex Mitchell www.psycho-oncology.info
Department of Cancer & Molecular Medicine, Leicester Royal Infirmary
Department of Liaison Psychiatry, Leicester General Hospital
Portugal 2010Portugal 2010
IX Congresso Portugues de Psico-Oncologia
How do investigations inform clinical practice?
IX Congresso Portugues de Psico-Oncologia
How do investigations inform clinical practice?
![Page 2: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/2.jpg)
T1. BackgroundT1. Background
Survivorship
Treatment rates
![Page 3: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/3.jpg)
10.9million incident cases (1mi breast, lung colorectal); 25mi prevalent cases
![Page 4: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/4.jpg)
0
10
20
30
40
50
60
70
80
90
100
Melanom
aBrea
st (fe
male)
Urinary
bladde
r
Prostat
e
Colon
All site
s
Rectum
Non-H
odgkin
lymph
oma
Ovary
Leuk
emiaLu
ng and
bron
chus
Pancre
as
1975-19771984-19861996-2004Change
5 Year Survival in US Cancers
![Page 5: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/5.jpg)
![Page 6: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/6.jpg)
Suicidal ThoughtsSuicidal ThoughtsStudied 554 (411 BW 143 BSA).
We measured suicidal thoughts :
not at all 0; several days 1; more than half the days 2; nearlyevery day 3. We report here, the proportion of people with any suicidal thoughts (non zero scores).
All = 8%Of major or minor depression. 22% had suicidal thoughtsOf major depression 36% had suicidal thoughts (45% BW)Of those with distress 18.0%
![Page 7: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/7.jpg)
% Receiving Any treatment for Depression% Receiving Any treatment for Depression
10.9 11.3
8.18.8
4.3
5.6
10.9
13.8
6.8
17.9
3.4
5.5
15.4
7.2
0
2
4
6
8
10
12
14
16
18
20
High Inc
omeBelg
ium
France
German
y
Israe
l
Italy
Japa
nNeth
erlan
dsNew
Zeala
nd
Spain USALow
Inco
me
ChinaColom
biaSouth
Afri
caUkra
ine
Wang P et al (2007) Lancet 2007; 370: 841–50
n=84,850 face-to-face interviews
![Page 8: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/8.jpg)
% Receiving Any treatment for Mental Health% Receiving Any treatment for Mental Health
7.2
34.6
5.7 6.3 6.4
11.7
19.1
14
8.9
3.9 3.25.7
32.7
5 57.7
11
16.1
6.5 6.2
2.3 1.8
0
5
10
15
20
25
30
35
40
All P
atie
nts
Men
tal I
ll Hea
lth
No
Men
tal I
ll He
alth
No
chro
nic m
edic
al co
nditi
ons
1 ch
roni
c m
edica
l con
ditio
n2
chro
nic
med
ical c
ondi
tions
3 ch
roni
c m
edica
l con
ditio
ns
18-4
4 ye
ars
45-6
4 ye
ars
65-7
4 ye
ars
75+
Cancer n=4878
No Cancer n=90,737
Maria Hewitt, Julia H. Rowland Mental Health Service Use Among Adult Cancer Survivors: Analyses of the National Health Interview Survey Journal of Clinical Oncology, Vol 20, Issue 23 (December), 2002: 4581-4590
![Page 9: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/9.jpg)
Q. Why Low Treatment Rates?Q. Why Low Treatment Rates?
Clinicians?
Patients?
![Page 10: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/10.jpg)
94.2%
37.4%
8 yrs N= 9282 NCS‐R
![Page 11: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/11.jpg)
n=226Comment: Frequency of cancer specialists enquiry about depression/distress from Mitchell et al (2008)
![Page 12: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/12.jpg)
Comment: Slide illustrates diagnostic accuracy according to score on DT
11.815.4
30.4 28.9
41.9 42.9 40.7
57.1
82.4
66.771.4
15.8
25.0
26.124.4
19.4 19.0
33.3
21.4
11.8
22.2 14.3
72.4
59.6
43.546.7
38.7 38.1
25.921.4
5.911.1
14.3
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Zero One Two Three Four Five Six Seven Eight Nine Ten
Judgement = Non-distressedJudgement = UnclearJudgement = Distressed
![Page 13: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/13.jpg)
0
0.05
0.1
0.15
0.2
0.25
0.3
Eight
Nine Ten
Eleven
Twelv
eTh
irtee
nFo
urtee
n
Fiftee
nSixt
een
Seven
teen
Eighteen
Ninetee
n
Twen
tyTw
enty-
one
Proportion MissedProportion Recognized
HADS-D
![Page 14: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/14.jpg)
Testing Clinicians: A Meta-AnalysisTesting Clinicians: A Meta-Analysis
All cancer professionalsSE =39.5% and SP =77.3%.
OncologistsSE =38.1% and SP = 78.6%; a fraction correct of 65.4%.
By comparison nursesSE = 73% and SP = 55.4%; FC = of 60.0%.
When attempting to detect anxiety oncologists managedSE = 35.7%, SP = 89.0%, FC 81.3%.
Presented at IPOS2009
![Page 15: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/15.jpg)
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Pre-test Probability
Post
-test
Pro
babi
lity
Ave Confidence+
Ave Confidence-
Baseline Probability
Above Ave Confidence+
Above Ave Confidence-
High Confidence+
High Confidence-
Low confidence = more cautious, fewer false positives, more false negatives
High confidence = less cautious, more false positives, low false negatives
p180
![Page 16: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/16.jpg)
462 (42%)Meetable Needs
1093 (100%)Population
388 (84%)Aware of Need
172 (44%)Requested Help
80 (47%)Needs Met
462 needs
17.3%
322 DSMIV
25%
![Page 17: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/17.jpg)
Can tools (investigations) help?Can tools (investigations) help?
![Page 18: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/18.jpg)
![Page 19: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/19.jpg)
Q. How Common is the Problem?Q. How Common is the Problem?
Depression
Distress
Anxiety
![Page 20: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/20.jpg)
Requires depressed mood for most of the day, for most days (by subjective account or observation) for at least 2 years
The symptoms cause clinically significant distress OR impairment in social, occupational, or other important areas of functioning.
Requires persistently low mood two (or more) of the following six symptoms:
(1) poor appetite or overeating (2) Insomnia or hypersomnia(3) low energy or fatigue (4) low self-esteem (5) poor concentration or difficulty
making decisions (6) feelings of hopelessness
DSM-IV Dysthymic disorder
Acute: if the disturbance lasts less than 6 months Chronic: if the disturbance lasts for 6 months
These symptoms cause marked distress that is in excess of what would be expected from exposure to the stressor OR significant impairment in social or occupational (academic) functioning
Requires the development of emotional or behavioral symptoms in response to an identifiable stressor(s) occurring within 3 months of the onset of the stressor(s). Once the stressor has terminated, the symptoms do not persist for more than an additional 6 months.
DSM-IV Adjustment disorder
2 weeksThese symptoms cause clinically important distress OR impair work, social or personal functioning.
Requires two to four out of nine symptoms with at least at least one from the first two (depressed mood and loss of interest).
DSM-IV Minor Depressive Disorder
2 weeksThese symptoms cause clinically important distress OR impair work, social or personal functioning.
Requires five or more out of nine symptoms with at least at least one from the first two (depressed mood and loss of interest).
DSM-IV Major Depressive Disorder
2 weeks unless symptoms are unusually severe or of rapid onset).
At least some difficulty in continuing with ordinary work and social activities
Requires two of the first three symptoms (depressed mood, loss of interest in everyday activities, reduction in energy) plus at least two of the remaining seven symptoms (minimum of four symptoms)
ICD-10 Depressive Episode
DurationClinical SignificanceSymptoms
![Page 21: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/21.jpg)
Depression
13%
20%
57%
48%
38%
18%
Anxiety
Adjustment Disorder
N=11N=4
N=10
Comment: Slide illustrates meta-analytic rates of mood disorder
![Page 22: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/22.jpg)
Prevalence of depression in Palliative settings
20 studies involving 2655 individuals
16.9% (95% CI = 13.2% to 21.0%)
13.0% (95% CI = 11.6% to 14.5%) for MDD
p572
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.17 (0.13, 0.21)
Maguire et al (1999) 0.05 (0.01, 0.14)
Akechi et al (2004) 0.07 (0.04, 0.11)
Kadan-Lottich et al (2005) 0.07 (0.04, 0.11)
Love et al (2004) 0.07 (0.04, 0.11)
Wilson et al (2004) 0.12 (0.05, 0.22)
Chochinov et al (1997) 0.12 (0.08, 0.18)
Wilson et al (2007) 0.13 (0.10, 0.17)
Kelly et al (2004) 0.14 (0.06, 0.26)
Chochinov et al (1994) 0.17 (0.11, 0.24)
Le Fevre et al (1999) 0.18 (0.10, 0.28)
Breitbart et al (2000) 0.18 (0.11, 0.28)
Meyer et al (2003) 0.20 (0.10, 0.35)
Minagawa et al (1996) 0.20 (0.11, 0.34)
Lloyd-Williams et al (2001) 0.22 (0.14, 0.31)
Hopwood et al (1991) 0.25 (0.16, 0.36)
Desai et al (1999) [late] 0.25 (0.10, 0.47)
Payne et al (2007) 0.26 (0.19, 0.33)
Lloyd-Williams et al (2003) 0.27 (0.17, 0.39)
Jen et al (2006) 0.27 (0.19, 0.36)
Lloyd-Williams et al (2007) 0.30 (0.24, 0.36)
proportion (95% confidence interval)
![Page 23: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/23.jpg)
Prevalence of depression in Oncology settings
57 studies involving 9195 individuals across 12 countries.
The prevalence of depression was 17.3% (95% CI = 13.8% to 21.2%),
13.0% (95% CI = 11.6% to 14.5%) for MDD
p572
Proportion meta-analysis plot [random effects]
0.0 0.3 0.6 0.9
combined 0.1730 (0.1375, 0.2116)
Colon et al (1991) 0.0100 (0.0003, 0.0545)
Massie and Holland (1987) 0.0147 (0.0063, 0.0287)
Hardman et al (1989) 0.0317 (0.0087, 0.0793)
Derogatis et al (1983) 0.0372 (0.0162, 0.0720)
Lansky et al (1985) 0.0455 (0.0291, 0.0676)
Mehnert et al (2007) 0.0472 (0.0175, 0.1000)
Katz et al (2004) 0.0500 (0.0104, 0.1392)
Singer et al (2008) 0.0519 (0.0300, 0.0830)
Sneeuw et al (1994) 0.0540 (0.0367, 0.0761)
Pasacreta et al (1997) 0.0633 (0.0209, 0.1416)
Lee et al (1992) 0.0660 (0.0356, 0.1102)
Reuter and Hart (2001) 0.0761 (0.0422, 0.1244)
Grassi et al (2009) 0.0826 (0.0385, 0.1510)
Grassi et al (1993) 0.0828 (0.0448, 0.1374)
Walker et al (2007) 0.0831 (0.0568, 0.1165)
Kawase et al (2006) 0.0851 (0.0553, 0.1240)
Coyne et al (2004) 0.0885 (0.0433, 0.1567)
Alexander et al (2010) 0.0900 (0.0542, 0.1385)
Love et al (2002) 0.0957 (0.0650, 0.1346)
Ozalp et al (2008) 0.0971 (0.0576, 0.1510)
Morasso et al (2001) 0.0985 (0.0535, 0.1625)
Costantini et al (1999) 0.0985 (0.0535, 0.1625)
Silberfarb et al (1980) 0.1027 (0.0587, 0.1638)
Desai et al (1999) [early] 0.1111 (0.0371, 0.2405)
Morasso et al (1996) 0.1121 (0.0593, 0.1877)
Prieto et al (2002) 0.1227 (0.0825, 0.1735)
Ibbotson et al (1994) 0.1242 (0.0776, 0.1853)
Payne et al (1999) 0.1290 (0.0363, 0.2983)
Kugaya et al (1998) 0.1328 (0.0793, 0.2041)
Alexander et al (1993) 0.1333 (0.0594, 0.2459)
Gandubert et al (2009) 0.1597 (0.1040, 0.2300)
Razavi et al (1990) 0.1667 (0.1189, 0.2241)
Akizuki et al (2005) 0.1797 (0.1376, 0.2283)
Leopold et al (1998) 0.1887 (0.0944, 0.3197)
Devlen et al (1987) 0.1889 (0.1141, 0.2851)
Berard et al (1998) 0.1900 (0.1184, 0.2807)
Joffe et al (1986) 0.1905 (0.0545, 0.4191)
Berard et al (1998) 0.2100 (0.1349, 0.3029)
Maunsell et al (1992) 0.2146 (0.1605, 0.2772)
Grandi et al (1987) 0.2222 (0.0641, 0.4764)
Evans et al (1986) 0.2289 (0.1438, 0.3342)
Spiegel et al (1984) 0.2292 (0.1495, 0.3261)
Golden et al (1991) 0.2308 (0.1353, 0.3519)
Fallowfield et al (1990) 0.2565 (0.2054, 0.3131)
Hosaka and Aoki (1996) 0.2800 (0.1623, 0.4249)
Kathol et al (1990) 0.2961 (0.2248, 0.3754)
Green et al (1998) 0.3125 (0.2417, 0.3904)
Jenkins et al (1991) 0.3182 (0.1386, 0.5487)
Burgess et al (2005) 0.3317 (0.2672, 0.4012)
Hall et al (1999) 0.3722 (0.3139, 0.4333)
Morton et al (1984) 0.3958 (0.2577, 0.5473)
Baile et al (1992) 0.4000 (0.2570, 0.5567)
Passik et al (2001) 0.4167 (0.2907, 0.5512)
Bukberg et al (1984) 0.4194 (0.2951, 0.5515)
Massie et al (1979) 0.4850 (0.4303, 0.5401)
Ciaramella and Poli (2001) 0.4900 (0.3886, 0.5920)
Levine et al (1978) 0.5600 (0.4572, 0.6592)
Plumb & Holland (1981) 0.7750 (0.6679, 0.8609)
proportion (95% confidence interval)
![Page 24: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/24.jpg)
Distress Thermometer
![Page 25: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/25.jpg)
Distress Thermometer – Pooled Table
ScoreRansom 2006
Tuinman2008
Mitchell 2009
Lord 2010
Hoffman 2004
Gessler2009
Clover 2009
Jacobsen 2005 Sum
Proportion
Zero 68 38 61 123 14 27 65 71 467 18.4%
One 72 31 42 68 5 26 39 46 329 12.9%
Two 77 22 35 44 5 18 30 54 285 11.2%
Three 65 37 42 46 8 23 45 46 312 12.3%
Four 51 29 29 30 8 7 21 31 206 8.1%
Five 41 46 62 40 11 13 41 48 302 11.9%
Six 38 32 23 28 2 16 26 31 196 7.7%
Seven 36 21 23 38 2 15 32 16 183 7.2%
Eight 18 12 18 29 6 9 19 15 126 5.0%
Nine 16 5 8 14 3 3 13 9 71 2.8%
Ten 9 4 7 20 4 0 9 13 66 2.6%
Sum 491 277 350 480 68 157 340 380 2543
Proportion 19.3% 10.9% 13.8% 18.9% 2.7% 6.2% 13.4% 14.9%
![Page 26: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/26.jpg)
Proportion
18 .4 %
12 .9 %
11.2 %12 .3 %
8 .1%
11.9 %
5.0 %
2 .8 % 2 .6 %
7.7% 7.2 %
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
20.0%
Zero One Two Three Four Five Six Seven Eight Nine Ten
Insignificant SevereModerateMildMinimal
p124
50%
![Page 27: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/27.jpg)
ET - Table of Cut-PointsET - Table of Cut-Points
Distress Thermometer
Anxiety thermometer
Depression Thermometer
Anger Thermometer
Help Thermometer Cut-point
Insignificant 39.0 25.6 50.1 55.7 54.3 0,1
Minimal 20.1 22.5 18.3 13.6 15.4 2,3
Mild 16.9 16.5 12.2 10.5 12.2 4,5
Moderate 12.0 14.5 9.8 6.6 6.6 6,7
Severe 11.9 20.8 9.5 13.6 11.2 8,9,10
p130
![Page 28: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/28.jpg)
8%
DT37%
DepT23%
AngT18%
AnxT47%
4%
7%
1%
1%
9%
3%
0%
2%
4%
15%
3%
2%
Nil41%
Non-Nil59%
DT
AnxT AngT
DepT
![Page 29: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/29.jpg)
Q. Investigations => ScreeningQ. Investigations => Screening
What is available?
![Page 30: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/30.jpg)
Observation
Interview
Visual
Self-Report
DepressionScreening
DISCS
VA-SES
ET/DT
HAMD-D17
PhysicalGeneral
Signs ofDS
6
CDSS#10
MADRAS10
Trained
ConfidentSkilledClinician
Alone
YALE
SMILEY
![Page 31: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/31.jpg)
![Page 32: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/32.jpg)
Comment: This is a reminder of the structure of the HADS scale, this version adapter for cancer.
![Page 33: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/33.jpg)
Inadequate Data(n=11)
No data (n= 250)
No reference standard(n= 293)
Accuracy or Validity Analyses(n= 210)
HADS Validity Analyses(n=50)
HADS in CancerInitial Search (n= 768)
ScaleTypes
Sample Size (cases)
HADS-T(n=26)
HADS-D(n=14)
HADS-A(n=10)
Less than 30(n=22)
More than 100(n=8)
30 to 100(n=20)
Review articles (n= 16)
Depression(n=22)
Any Mental Ill Health(n=24)
Anxiety(n=4)
OutcomeMeasure
No interview standard(n=149)
![Page 34: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/34.jpg)
Validity of HADS vs depression (DSMIV)Validity of HADS vs depression (DSMIV)
SE 71.6% (68.3)
SP 82.6% (85.7)
Prev 13%
PPV 38%
NPV 95%
![Page 35: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/35.jpg)
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Pre-test Probability
Post
-test
Pro
babi
lity
HADS+
HADS-
Baseline Probability
HADS7v8+
HADS7v8-
Depression_HADS-d (7v8)
![Page 36: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/36.jpg)
Q. Why only depression / anxiety?Q. Why only depression / anxiety?
?
![Page 37: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/37.jpg)
![Page 38: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/38.jpg)
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
DistressThermometer
AnxietyThermometer
DepressionThermometer
AngerThermometer
TenNineEightSevenSixFiveFourThreeTwoOneZero
Comment: Slide illustrates scores on ET tool
![Page 39: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/39.jpg)
DT DepTVsHADS-A
AnxT AngT
AUC:DT=0.82DepT=0.84AnxT=0.87AngT=0.685
![Page 40: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/40.jpg)
6. How Valid Are the Tools6. How Valid Are the Tools
![Page 41: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/41.jpg)
![Page 42: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/42.jpg)
![Page 43: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/43.jpg)
DT vs HADS-T Validity (n=660)DT vs HADS-T Validity (n=660)
SE SP AUC CUT
DT – 71.9% 78.4% 0.814 cut point >=4
AnxT – 75.7% 73.4% 0.821 cut point >=5
DepT – 77.6% 82.2% 0.855 cut point >=3
AngT – 77.5% 77.6% 0.823 cut point >=2
HelpT - 69.1% 80.8% 0.809 cut point >=3
![Page 44: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/44.jpg)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Pre-test Probability
Pos
t-tes
t Pro
babi
lity
Baseline Probability
HADSd+
HADSd-
HADS-T+
HADS-T-
HADS-A+
HASD-A-
Depression_HADS
![Page 45: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/45.jpg)
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Pre-test Probability
Post
-test
Pro
babi
lity
1Q+1Q-Baseline ProbabilityDT+DT-2Q+2Q-HADSd+HADSd-HADS-T+HADS-T-BDI+BDI-EPDS+EPDS-HADS-A+HASD-A-
Depression_all
![Page 46: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/46.jpg)
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Pre-test Probability
Post
-test
Pro
babi
lity
DT+ [N=4]DT+ [N=4]Baseline Probability1Q+ [N=4]1Q- [N=4]2Q+2Q-DT/IT+DT/IT-HADST+ [N=13]HADST+ [N=13]PDI+PDI-
Mitchell AJ. Short Screening Tools for Cancer Related Distress A Review and Diagnostic Validity Meta-analysis JNCI (2010) in press
Distress
![Page 47: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/47.jpg)
Validity of DT vs depression (DSMIV)Validity of DT vs depression (DSMIV)
SE 80%
SP 60%
PPV 32%
NPV 93%
![Page 48: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/48.jpg)
DT vs DSMIV DepressionDT vs DSMIV Depression
SE SP PPV NPV
DTma 80.9% 60.2% 32.8% 92.9%
DTLeicesterBW 82.4% 68.6% 28.0% 98.3%
DTLeicesterBSA 100% 59.6% 26.8% 100%
BSA = British South Asian BW= British White
![Page 49: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/49.jpg)
Q. Problem with somatic symptoms?Q. Problem with somatic symptoms?
![Page 50: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/50.jpg)
Approaches to Somatic Symptoms of Depression
InclusiveUses all of the symptoms of depression, regardless of whether they may or may not be secondary
to a physical illness. This approach is used in the Schedule for Affective Disorders and Schizophrenia (SADS) and the Research Diagnostic Criteria.
ExclusiveEliminates somatic symptoms but without substitution. There is concern that this might lower
sensitivity. with an increased likelihood of missed cases (false negatives)
EtiologicAssesses the origin of each symptom and only counts a symptom of depression if it is clearly not
the result of the physical illness. This is proposed by the Structured Clinical Interview for DSM and Diagnostic Interview Schedule (DIS), as well as the DSM-III-R/IV).
SubstitutiveAssumes somatic symptoms are a contaminant and replaces these additional cognitive symptoms.
However it is not clear what specific symptoms should be substituted
![Page 51: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/51.jpg)
![Page 52: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/52.jpg)
![Page 53: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/53.jpg)
Medically Unwell Alone
Primary Depression Alone
Secondary Depression
Comment: Slide illustrates concept of phenomenology of depressions in medical disease
FatigueAnorexiaInsomnia
Concentration
![Page 54: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/54.jpg)
Study: Coyne Thombs MitchellN= 4500; Pooled database study; All comparative studies
Physical illness+comorbid depressionVsPhysical illness aloneVsPrimary depression alone
![Page 55: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/55.jpg)
Co-morbid Depression vs Primary Depression
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Agitatio
n (Com
orbid)
Agitatio
n (Prim
ary)
Anxiety
(Com
orbid)
Anxiety
(Prim
ary)
Appetite
(Comorb
id)
Appetite
(Prim
ary)
Concen
tratio
n (Comorb
id)
Concen
tratio
n (Prim
ary)
Fatigu
e (Comorb
id)
Fatigu
e (Prim
ary)
Guilt (
Comorbid)
Guilt (
Primar
y)
Hopeles
snes
s (Comorb
id)
Hopeles
snes
s (Prim
ary)
Insomnia
(Comor
bid)
Insomnia
(Prim
ary)
Loss In
teres
t (Comorb
id)
Loss In
teres
t (Prim
ary)
Low Mood (C
omorbid)
Low Mood (P
rimary
)
Retard
ation (
Comorbid)
Retard
ation (
Primary)
Suicide (
Comorbid)
Suicide (
Primar
y)
Weight L
oss (C
omorbid)
Weight L
oss (P
rimary
)
*
*
*
*
*
**
*
*
Comorbid Depression
Primary Depression
n=4069 vs 4982Comment: Slide illustrates similar symptoms profile in comorbid vsprimary depression
![Page 56: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/56.jpg)
Co-morbid Depression vs Medical Illness Alone
n= 4069 vs 1217
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Anxiety
(Com
orbid)
Anxiety
(Med
ical)
Concen
tratio
n (Comorb
id)
Concen
tratio
n (Med
ical)
Fatigu
e (Comorb
id)Fati
gue (
Medica
l)
Hopeles
snes
s (Comorb
id)
Hopeles
snes
s (Med
ical)
Insomnia
(any t
ype)
(Comorb
id)
Insomnia
(any t
ype)
(Med
ical)
Loss In
teres
t (Comorb
id)
Loss In
teres
t (Med
ical)
Low Mood (C
omorbid)
Low Mood (M
edical)
Retard
ation (
Comorbid)
Retard
ation (
Medica
l)
Suicide (
Comorbid)
Suicide (
Medica
l)
Weight L
oss (C
omorbid)
Weight L
oss (M
edical)
Worthles
snes
s (Comor
bid)
Worthles
snes
s (Med
ical)
Medical Illness Alone
Comorbid Depression
**
*
*
*
*
*
*
*
Comment: Slide illustrates distinct symptoms profile in comorbid depression vs medical illness alone
![Page 57: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/57.jpg)
Medically Unwell Alone
Primary Depression Alone
Secondary Depression
Comment: Slide illustrates concept of phenomenology of depressions in medical disease
FatigueAnorexiaInsomnia
Concentration
![Page 58: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/58.jpg)
Medically Unwell
Primary Depression
Secondary Depression
Comment: Slide illustrates actual phenomenology of depressions in medical disease
Weight loss
AgitationRetardation
![Page 59: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/59.jpg)
Q. How to Choose A Cut-OffQ. How to Choose A Cut-Off
![Page 60: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/60.jpg)
British Journal of Cancer (2007) 96, 868 – 874
![Page 61: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/61.jpg)
Distress Thermometer
![Page 62: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/62.jpg)
Distress Thermometer – PooledProportion
18 .4 %
12 .9 %
11.2 %12 .3 %
8 .1%
11.9 %
5.0 %
2 .8 % 2 .6 %
7.7% 7.2 %
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
20.0%
Zero One Two Three Four Five Six Seven Eight Nine Ten
Insignificant SevereModerateMildMinimal
p124
50%
![Page 63: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/63.jpg)
PHQ9 Linear distribution
0
5
10
15
20
25
30
35
Zero One Two
Three
Four
Five Six
Seven
Eight
Nine
TenElev
enTwelveThir
teen
Fourte
enFifte
enSixt
een
Sevente
enEigh
teen
PHQ9 (Major Depression)PHQ9 (Minor Depression)PHQ9 (Non-Depressed)
Baker-Glen, Mitchell et al (2008)
![Page 64: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/64.jpg)
SampleSample
We analysed data collected from Leicester Cancer Centre from 2008-2010 involving 531 people approached by a research nurse and two therapeutic radiographers.
We examined distress using the DT and daily function using the question:
“How difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?”
“Not difficult at all =0; Somewhat Difficult =1; Very Difficult =2; and Extremely Difficult =3”
![Page 65: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/65.jpg)
Dysfunction in 531 cancer patientsDysfunction in 531 cancer patients
55.7%
34.3%
7.3%
2.6%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
Unimpaired Mild Moderate Severe
![Page 66: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/66.jpg)
Unimpaired by DT ScoreUnimpaired by DT Score
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
1 2 3 4 5 6 7 8 9 10 11
![Page 67: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/67.jpg)
18%
DepT23%
Distress69%
Dysfunction76%
0.3%
3% 2%
26%28% 22%
Of the 293 Non-Nil
DysfunctionDistress
DepT
![Page 68: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/68.jpg)
DT distribution by ImpairmentDT distribution by Impairment
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
0 1 2 3 4 5 6 7 8 9 10
![Page 69: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/69.jpg)
Extreme and incapacitating
Very Severe and very disabling
Moderately Severe and disabling
Moderate and quite disabling
Moderate and somewhat disabling
Mild-Moderate and slight disabling
Mild but not particularly disabling
Very mild and not disabling
Minimal but bearable
Minimal and not problematic
None at all
![Page 70: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/70.jpg)
![Page 71: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/71.jpg)
![Page 72: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/72.jpg)
T4. Screening in Cancer: ImplementationT4. Screening in Cancer: Implementation
Clinician Opinion
Patient Opinion
![Page 73: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/73.jpg)
1,2 or 3 Simple QQ24%
Clinical Skills Alone20%
ICD10/DSMIV24%
Short QQ24%
Long QQ8%
Algorithm26%
Short QQ23%
ICD10/DSMIV0%
Clinical Skills Alone17%
1,2 or 3 Simple QQ34%
Cancer StaffIdeal Method (n=226)
Psychiatrists
Effective?
Comment: “Ideal” method of eliciting symptoms of distress/depression according to clinician
![Page 74: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/74.jpg)
![Page 75: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/75.jpg)
Comment: Slide illustrates actual gain in meta-analysis of screening implementation in primary care
![Page 76: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/76.jpg)
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Pre-test Probability
Post
-test
Pro
babi
lity
Clinical+Clinical-Baseline ProbabilityScreen+Screen-
Comment: Slide illustrates Bayesian curve comparison from RCT studies of clinician with and without screening
This illustrates ACTUAL gain from screening in Study from Christensen
![Page 77: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/77.jpg)
800 Patients Approached
100 Not Willing (13%) 700 Patients Willing (87%)
500 Staff Willing (71%)TAU
402 Data Collected (80%)Screen Data
Leicester: UptakeLeicester: Uptake T177 t680
![Page 78: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/78.jpg)
Pre-Post Screen - DistressPre-Post Screen - Distress
Before After
Sensitivity of 49.7%
Specificity of 79.3%
PPV was 67.3%
NPV was 64.1%
![Page 79: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/79.jpg)
Pre-Post Screen - DistressPre-Post Screen - Distress
Before After
Sensitivity of 49.7% 55.8% =>+5%
Specificity of 79.3% 79.8% =>+1%
PPV was 67.3% 70.9% =>+4%
NPV was 64.1% 67.2% =>+3%
There was a non-significant trend for improve detection sensitivity (Chi² = 1.12 P = 0.29).
![Page 80: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/80.jpg)
Qualitative AspectsQualitative Aspects
DISTRESS
43% of CNS reported the tool helped them talk with the patient about psychosocial issues esp in those with distress
28% said it helped inform their clinical judgement
DEPRESSION
38% of occasions reported useful in improving communication.
28.6% useful for informing clinical judgement
![Page 81: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/81.jpg)
Next StepNext Step269 Nurse-patient
interactions
Helped 65 (24%) Not Helped 204 (76%)
Unmet Needs 150 (55.8%)
Referred 23 (8.6%) Declined Helped 20 (7.4%)
No Unmet Needs 34 (12.6%)
p179
![Page 82: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/82.jpg)
2x2 Clinician Help Table : ACTUAL HELP2x2 Clinician Help Table : ACTUAL HELP
Clinician thinks:Unmet Needs
Clinician thinks no Unmet Needs
Patient Says:Help Wanted (60)
Helped 21/35 (60%)
Helped 11/23(48%)
Patient Distressed
Helped 65/102(63%)
Helped 31/62(50%)
Patient Not distressed orHelp Not Wanted
Helped 8/35(23%)
Helped 20/117(17%)
![Page 83: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/83.jpg)
b. Intervention and helpb. Intervention and helpPREDICTORS
1. patient desire for help
2. number of unmet needs
3. clinicians confidence
4. patient reported anger
p179
![Page 84: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/84.jpg)
RCT using DT Carlson et al 2010RCT using DT Carlson et al 2010
Screening for Distress in lung and breast cancer outpatients: A randomized controlled trial Linda Carlson Tom Baker Cancer Centre, University of Calgary
1) Minimal Screening: the Distress Thermometer (DT) [n=365]
2) Full Screening: DT, Problem Checklist, Psychological Screen for Cancer (PSSCAN) [n=391] a personalized report
3) Triage: Full screening plus optional personalized phone triage [378]
![Page 85: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/85.jpg)
![Page 86: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/86.jpg)
![Page 87: Keynote - How Do Investigations in Psycho-oncology Inform Clinical Practice? (Oct01](https://reader034.vdocument.in/reader034/viewer/2022051411/5413f9118d7f7294698b47b1/html5/thumbnails/87.jpg)
FURTHER READING:
Screening for Depression in Clinical Practice An Evidence-Based guide
ISBN 0195380193 Paperback, 416 pagesNov 2009Price: £39.99